Amniotic Fluid Reduces Liver Fibrosis By Attenuating Hepatic Stellate Cell Activation

ABSTRACT: Chronic activation of hepatic stellate cells leads to irreversible liver fibrosis, and durable treatment options for liver fibrosis remain suboptimal, creating a critical clinical need. Amniotic fluid (AF) reduces inflammation and promotes tissue remodeling and regeneration when applied to cutaneous wounds and in models thereof. However, no prior studies have explored the anti-fibrotic benefits of AF in liver disease. Data from this study indicate that AF can repress liver fibrosis by reducing hepatic stellate cell myofibroblast activation. Thus, these findings lay the foundation for early-phase clinical trials investigating cell-free AF as a therapeutic treatment for liver fibrosis and as a bridging therapy for liver transplantation

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Amniotic Fluid

SUBMITTER: William Russell  

LAB HEAD: W. Samuel Fagg

PROVIDER: PXD060743 | Pride | 2025-07-14

REPOSITORIES: Pride